Clinical-stage radiopharmaceutical company Oncoinvent ASA (Euronext Growth Oslo:ONCIN) and Thor Medical ASA (OSE:TRMED), a supplier of alpha-emitters for precision cancer treatment, on Friday announced a strategic supply agreement for thorium-228 to support Oncoinvent's Phase 3 clinical programme for Radspherin, its lead radiopharmaceutical candidate.

Thor Medical will provide thorium-228 from AlphaOne, its first commercial-scale manufacturing facility currently under construction. The isotope will be used to produce radium-224, a core component of Radspherin designed to directly target cancers in body cavities.

Oncoinvent is advancing a randomised Phase 2 trial of Radspherin in peritoneal carcinomatosis from ovarian cancer, with Phase 3 development supported by the new supply arrangement.

Both companies are headquartered in Oslo, underscoring Norway's growing role as a hub for radiopharmaceutical innovation and targeted alpha therapies. This agreement highlights the country's expanding ecosystem of scientific, clinical, and industrial expertise in oncology-focused nuclear medicine.